Ruijin Hospital: Lymphoma, Large B-Cell, Diffuse trials

The registry lists 36 Lymphoma, Large B-Cell, Diffuse studies with Ruijin Hospital as lead sponsor. 21 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 16Phase 3 7Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLRecruitingNCT06803693Phase 2
• PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell LymphomaRecruitingNCT06755775
• Dynamic CtDNA-guided Targeted Therapy in DLBCLNot yet recruitingNCT06748521Phase 2
• Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
• The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter StudyNot yet recruitingNCT06656234
• Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor LymphomaNot yet recruitingNCT06652152
• Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC PositiveNot yet recruitingNCT06652139Phase 2
• Autologous Hematopoietic Stem Cell Boost Study After CAR-T TherapyRecruitingNCT06589089Phase 2
• A Real-World Study on Extranodal LymphomaNot yet recruitingNCT06573099
• The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
• Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
• Real-World Study of DLBCL With Different Genetic SubtypesRecruitingNCT06026488
• Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell LymphomaNot yet recruitingNCT05923879
• (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Not yet recruitingNCT05923502
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
• A Combination Study of CAR-T Therapy in r/r B-NHLRecruitingNCT05871684Phase 2
• Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNCT05863845Not applicable
• Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
• Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
• The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 YearsRecruitingNCT05179733Phase 3
• The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low RiskRecruitingNCT05018520Phase 3
• A Retrospective Study on Extranodal DLBCLCompletedNCT06549361
• Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05189782
• PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCTStatus unknownNCT04799314Phase 3
• PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCTStatus unknownNCT04789434Phase 3
• Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
• Biomarker Guided Treatment in DLBCLStatus unknownNCT04025593Phase 2
• Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
• Lenalidomide Based Immunotherapy in the Treatment of DLBCLStatus unknownNCT03715296
• A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma PatientsStatus unknownNCT03600363Phase 2
• Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
• Decitabine Plus R-CHOP in Diffuse Large B-cell LymphomaStatus unknownNCT02951728Phase 1/2
• Chidamide Plus R-CHOP in Elderly DLBCLStatus unknownNCT02753647Phase 2
• Reduced Chemotherapy in Low Risk DLBCLStatus unknownNCT02752815Phase 4
• A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCLStatus unknownNCT02542111Phase 2
• R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3BStatus unknownNCT01852435Phase 3